Hologic (HOLX) Q3 2025: Endomag Revenue Hits $20M, Accelerating Breast Health Rebound
Endomag, breast surgery device business, delivered nearly $20 million in revenue, validating Hologic’s commercial reset and underpinning a sequential rebound in Breast Health. Disciplined cost controls and tariff mitigation preserved margins despite product mix shifts and international headwinds. Management is signaling a return to mid-single-digit organic growth in fiscal 2026, underpinned by execution in core diagnostics and the late-2026 Envision launch.
Summary
- Breast Health Turnaround: Commercial reorganization and Endomag integration are driving sequential improvement and renewed optimism.
- Diagnostics Resilience: Panther platform and molecular assay adoption offset China and HIV funding headwinds.
- Margin Stability: Tariff mitigation and cost discipline support sustained profitability despite product transitions.
Performance Analysis
Hologic’s Q3 results highlight a company regaining operational momentum after recent turbulence. Total revenue slightly exceeded internal expectations, with the Diagnostics division growing organically outside of COVID-19, and Breast Health showing sequential improvement despite ongoing year-over-year declines. The standout was the Endomag business, acquired last year, which contributed nearly $20 million in revenue and is now accretive to organic growth calculations. Interventional Breast Health, which includes Endomag, grew 31.8% (6% organically excluding acquisitions), signaling the impact of a refocused sales force and portfolio expansion.
Margin performance reflected both headwinds and resilience. Non-GAAP operating margin remained above 30%—a best-in-class level—despite an 80 basis point gross margin decline driven by product mix and the planned discontinuation of the low-margin FloraScan system. Operating expenses rose modestly due to recent acquisitions, but would have declined 4.3% excluding those deals, underscoring management’s ongoing cost vigilance. Operating cash flow was robust at $343 million, supporting $750 million in year-to-date buybacks and maintaining a net leverage ratio of 0.6x.
- Breast Health Sequential Uptick: 3D gantry shipments increased sequentially, and interventional sales reached a $100 million quarterly milestone.
- Diagnostics Organic Growth: Panther Fusion and BVCV-TB drove U.S. molecular growth of 7.3% (ex-COVID), offsetting international softness.
- Tariff Headwind Halved: Supply chain actions reduced expected tariff impact to $10–12 million per quarter, down from $20–25 million.
Growth was broad-based in Surgical (up 6.3%) and Skeletal Health (up 62.1%), though the latter benefited from pent-up demand and will moderate as FloraScan is discontinued. The company’s ability to manage through adverse conditions in China and Africa, while delivering on guidance, points to operational discipline and a clearer growth trajectory for fiscal 2026.
Executive Commentary
"Progress in exceeding our near-term financial commitments, progress in strengthening our breast health business, and progress toward accelerating overall company growth in the fourth quarter, as well as 26 and beyond. All in all, we are confident in our path and optimistic about our future."
Steve McMillan, Chairman, President, and CEO
"Our strong profitability helps to drive excellent cash generation, as we delivered $343 million of operating cash flow in the third quarter. We finished the quarter with $1.88 billion in cash, and short-term investments on our balance sheet and a net leverage ratio of 0.6 times."
Carlene Oberton, Chief Financial Officer
Strategic Positioning
1. Breast Health: Commercial Reset and Portfolio Expansion
Hologic’s breast health franchise is regaining momentum through targeted commercial reorganization and product innovation. The company’s bifurcated sales structure and new upgrade strategy for end-of-life gantries are starting to deliver, with sequential growth in 3D gantry shipments and a robust pipeline for the Envision system launch in late 2026. Endomag integration is exceeding deal expectations, providing both recurring revenue and margin uplift, while the Genius AI Detection Pro software launch positions Hologic at the forefront of AI-enabled radiology.
2. Diagnostics: Panther Ecosystem and Menu Expansion
The Panther platform, automated molecular diagnostics system, remains a bedrock of growth. Panther Fusion adoption continues, with open access capabilities allowing labs to consolidate testing and run lab-developed assays. While China and HIV-related funding cuts are pressuring international diagnostics, U.S. molecular growth remains strong, and menu expansion for Fusion is expected to contribute meaningfully from fiscal 2027 onward. Genius digital cytology is driving workflow transformation and supporting resilience in cytology.
3. Tariff Mitigation and Cost Discipline
Hologic’s supply chain and procurement initiatives have halved the anticipated tariff headwind, reducing the impact to $10–12 million per quarter. This, combined with operating expense controls (down 4.3% excluding acquisitions), supports margin stability even as the company transitions away from lower-margin legacy products like FloraScan. Management’s focus on operational efficiency is enabling reinvestment in innovation and commercial capabilities.
4. Surgical and International Growth Levers
International surgical sales grew nearly 25%, reflecting investments in commercial reach and reimbursement expansion outside the U.S. NovaSure, minimally invasive endometrial ablation product, continues to deliver double-digit international growth, demonstrating the potential for global expansion of Hologic’s women’s health portfolio. Management expects international to be accretive to total company growth over the strategic planning horizon.
5. Capital Allocation and M&A Discipline
Year-to-date buybacks exceeded $750 million, with management emphasizing a balanced approach between repurchases and targeted tuck-in M&A. The focus remains on bolt-on deals that extend the women’s health continuum, as exemplified by Endomag, rather than large transformative transactions. The strong balance sheet and refinancing provide strategic flexibility for future opportunities.
Key Considerations
Hologic’s third quarter marks a turning point, with the company demonstrating progress on multiple fronts and setting up for a return to sustainable growth in fiscal 2026. The recovery in Breast Health, resilience in Diagnostics, and disciplined cost management are key pillars supporting this outlook.
Key Considerations:
- Endomag Outperformance: Direct sales integration is driving both top-line growth and margin accretion in the interventional portfolio.
- Breast Health Upgrade Cycle: The new strategy to replace aging gantries is gaining traction, with Envision expected to accelerate adoption in late 2026 and beyond.
- China and HIV Headwinds: International diagnostics will remain pressured through the first half of fiscal 2026, with China revenue down over 50% year-over-year.
- Menu Expansion Pace: Panther Fusion menu additions will be incremental, with material revenue impact expected only from fiscal 2027.
- Margin Management: FloraScan discontinuation and tariff mitigation are critical to preserving best-in-class profitability as product mix evolves.
Risks
Persistent headwinds in China and Africa, including funding cuts and regulatory challenges, will continue to weigh on Diagnostics growth through at least the first half of fiscal 2026. Tariff exposure remains dynamic, and further supply chain disruptions could pressure margins. The pace of Breast Health recovery hinges on successful execution of the commercial reset and new product launches, with competitive dynamics and replacement cycles representing ongoing uncertainties.
Forward Outlook
For Q4 2025, Hologic guided to:
- Total revenue of $1.03–1.04 billion
- Non-GAAP EPS of $1.09–1.12
For full-year 2025, management raised guidance midpoints:
- Revenue of $4.081–4.091 billion
- Non-GAAP EPS of $4.23–4.26
Management highlighted several factors that will shape Q4 and fiscal 2026:
- Breast Health is expected to return to growth in Q4, with further acceleration in 2026 as Envision launches.
- Diagnostics international headwinds from China and HIV will persist into the first half of 2026, but core U.S. molecular growth remains robust.
Takeaways
Hologic’s Q3 demonstrates tangible progress across commercial, operational, and financial dimensions, setting the stage for a return to mid-single-digit organic growth in fiscal 2026.
- Breast Health Inflection: Commercial overhaul and Endomag integration are driving sequential improvement and restoring management’s confidence in the segment’s growth trajectory.
- Diagnostics Foundation: Panther platform and menu expansion are offsetting geographic headwinds, underpinning long-term resilience and recurring revenue streams.
- Margin and Cash Flow Discipline: Proactive cost controls and tariff mitigation are preserving profitability and enabling continued capital deployment for growth and shareholder returns.
Conclusion
Hologic’s third quarter marks a shift from stabilization to renewed momentum, with Breast Health and Diagnostics providing dual engines for future growth. Management’s operational discipline and capital allocation prudence position the company to capitalize on innovation and commercial execution as it enters fiscal 2026.
Industry Read-Through
Hologic’s experience underscores the importance of commercial agility and product innovation in medtech, particularly as legacy upgrade cycles lengthen and international markets remain volatile. The rapid integration and outperformance of Endomag highlight the value of targeted, accretive M&A in building recurring revenue streams. The company’s success in mitigating tariff headwinds and controlling costs provides a playbook for peers facing similar supply chain and regulatory pressures. Finally, sustained investment in AI-enabled diagnostics and workflow automation points to an industry-wide shift toward digital transformation and efficiency in women’s health and laboratory testing.